ArticleFrontiers in immunology2025
Increased IgG4 expression within tertiary lymphoid structures of esophageal cancer and implications for prognosis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Immunotherapy resistance and strategies in malignant pleural mesothelioma.Cancer drug resistance (Alhambra, Calif.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tertiary lymphoid structures (TLS) have been observed in various tumors, including esophageal squamous cell carcinoma (ESCC), where they function as active centers of humoral immunity within the tumor microenvironment, facilitating the production of distinct immunoglobulin (Ig) subtypes with diverse effects. This study aimed to investigate the expression of TLS-associated Ig in ESCC and its prognostic significance. Methods: A retrospective analysis was conducted on 109 ESCC cases. TLS presence was evaluated using immunohistochemistry, and the expression of Ig-positive cells was assessed. Additionally, gene expression profiles related to TLS were analyzed with gene chip data from 274 ESCC cases obtained from the GEO database. Results: Among the 109 ESCC cases, 69 (63.3%) exhibited TLS, while 40 (36.7%) did not. Patients with TLS demonstrated significantly better prognoses compared to those without TLS (P < 0.001). ESCC tumor tissues with TLS exhibited higher infiltration of Ig-positive immune cells. Among the variables examined, the differential expression of IgG4 was the most pronounced (P = 0.04). Furthermore, ESCC cases exhibiting TLS with elevated IgG4 expression demonstrated a poorer prognosis compared to those with TLS and reduced IgG4 expression (P = 0.036). The presence of TLS in general and low IgG4 expression in TLS were associated with improved survivals in patients who underwent post-surgery chemotherapy (p < 0.001 and p = 0.001, respectively). Analysis of the GEO dataset indicated that predominant IgG4 expression within TLS was associated with a reduced number of activated CD8+ T cells and an increased presence of CD4+ T helper cells and dendritic cells. The expression of TLS in ESCC was linked to a more favorable prognosis, whereas TLS with increased IgG4 expression correlated with a less favorable prognosis. Conclusions: The differential expression of immunoglobulins within TLS can modulate its function within the tumor microenvironment. In addition to the number of TLSs themselves, the immune heterogeneity present within TLS maybe a critical factor in individualized assessment of tumor immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.